tetano
Editor, Senior Moderator
J Clin Neurosci
. 2022 Feb 24;99:311-316.
doi: 10.1016/j.jocn.2022.02.033. Online ahead of print.
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East
Raed Alroughani[SUP] 1 [/SUP], Jihad Inshasi[SUP] 2 [/SUP], Jasem Al-Hashel[SUP] 3 [/SUP], Jaber Alkhaboury[SUP] 4 [/SUP], Abdullah Alsalti[SUP] 5 [/SUP], Reem Al Suwaidi[SUP] 6 [/SUP], Loqman H Hassino[SUP] 7 [/SUP], Samar Farouk Ahmed[SUP] 8 [/SUP]
Affiliations
Abstract
A cross-sectional hospital records-based study was conducted to evaluate the prevalence, severity, outcomes, and identify demographic and clinical risk factors of coronavirus disease (COVID-19) in patients with MS. The study was conducted at multiple clinics in Oman, Kuwait, and the United Arab Emirates (UAE) from March 2020 to February 2021. The association of patient demographics, MS disease characteristics, and use of disease-modifying therapies with outcomes of COVID-19 illness were evaluated using odds ratio. A total of 134 MS patients with COVID-19 (prevalence rate of 3.7%) having a median age of 35.5 years were analyzed in the study. A majority (126 [94.0%]) of patients had mild COVID-19 illness and 122 (91.0%) made a full recovery, while 1 (0.7%) patient died. The median EDSS score reported in the study was low (1.0). Univariate regression analysis showed high EDSS scores, progressive MS disease, and use of anti-CD20 therapy such as rituximab as risk factors for moderate to severe COVID-19 requiring hospitalization. Comorbidities were associated with a higher risk of non-recovery from COVID-19 in both univariate and multivariate analyses. Age, sex, smoking history, and duration of MS did not show a significant association with severity or adverse COVID-19 disease outcome. Identification of risk factors can aid in improving the treatment and monitoring of pwMS and COVID-19.
Keywords: Anti-CD20 therapy; COVID-19; Comorbidity; Disease-modifying therapy; Multiple sclerosis; Regression analyses, odds ratio.
. 2022 Feb 24;99:311-316.
doi: 10.1016/j.jocn.2022.02.033. Online ahead of print.
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East
Raed Alroughani[SUP] 1 [/SUP], Jihad Inshasi[SUP] 2 [/SUP], Jasem Al-Hashel[SUP] 3 [/SUP], Jaber Alkhaboury[SUP] 4 [/SUP], Abdullah Alsalti[SUP] 5 [/SUP], Reem Al Suwaidi[SUP] 6 [/SUP], Loqman H Hassino[SUP] 7 [/SUP], Samar Farouk Ahmed[SUP] 8 [/SUP]
Affiliations
- PMID: 35339046
- PMCID: PMC8866083
- DOI: 10.1016/j.jocn.2022.02.033
Abstract
A cross-sectional hospital records-based study was conducted to evaluate the prevalence, severity, outcomes, and identify demographic and clinical risk factors of coronavirus disease (COVID-19) in patients with MS. The study was conducted at multiple clinics in Oman, Kuwait, and the United Arab Emirates (UAE) from March 2020 to February 2021. The association of patient demographics, MS disease characteristics, and use of disease-modifying therapies with outcomes of COVID-19 illness were evaluated using odds ratio. A total of 134 MS patients with COVID-19 (prevalence rate of 3.7%) having a median age of 35.5 years were analyzed in the study. A majority (126 [94.0%]) of patients had mild COVID-19 illness and 122 (91.0%) made a full recovery, while 1 (0.7%) patient died. The median EDSS score reported in the study was low (1.0). Univariate regression analysis showed high EDSS scores, progressive MS disease, and use of anti-CD20 therapy such as rituximab as risk factors for moderate to severe COVID-19 requiring hospitalization. Comorbidities were associated with a higher risk of non-recovery from COVID-19 in both univariate and multivariate analyses. Age, sex, smoking history, and duration of MS did not show a significant association with severity or adverse COVID-19 disease outcome. Identification of risk factors can aid in improving the treatment and monitoring of pwMS and COVID-19.
Keywords: Anti-CD20 therapy; COVID-19; Comorbidity; Disease-modifying therapy; Multiple sclerosis; Regression analyses, odds ratio.